Targeted Delivery of Liposomes to the Primate Maternal-Fetal Interface

将脂质体靶向递送至灵长类母胎界面

• 批准号: 9979328
• 负责人: THADDEUS G GOLOS
• 金额: $ 19.56万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-16 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9979328
• 关键词: Address; Area; Biological; Biological Markers; Blood flow; Caliber; Development; Endothelium; Experimental Models; Failure; Fetal Growth Retardation; Fetal Tissues; Fetal Weight; Fetal health; Fetus; Formulation; Goals; Health; Histopathology; Homing; Human; Image; Immune response; In Vitro; Infection; Inflammatory Response; Insulin-Like Growth Factor II; Intervention; Investigational Therapies; Knowledge; Lesion; Liposomes; Macaca; Macaca mulatta; Magnetic Resonance Imaging; Maternal Physiology; Maternal-Fetal Exchange; Measurement; Methods; Modeling; Monitor; Mothers; Mus; National Institute of Child Health and Human Development; Neonatal; Nitric Oxide Donors; Organ; Outcome; Peptides; Perfusion; Personal Satisfaction; Physiological; Placenta; Placental Biology; Placental Insufficiency; Placentation; Positioning Attribute; Pregnancy; Pregnancy Complications; Pregnant Women; Preparation; Primates; Publishing; Reagent; Research; Research Personnel; Rhesus; Risk; Rodent Model; Safety; Spiral Artery of the Endometrium; Structure; Therapeutic; Translating; Uterine Monitoring; Uterus; Weight; Work; adverse pregnancy outcome; clinically relevant; experience; fetal; gene therapy; healthy pregnancy; human model; improved; in vivo; in vivo Model; innovation; liposomal delivery; mouse model; nanoparticle; nonhuman primate; novel; particle; pregnant; prenatal therapy; prevent; protein aminoacid sequence; response; safety and feasibility; targeted delivery; trophoblast

The Human Placenta Project (HPP) has been launched by the NICHD to improve maternal and fetal/neonatal health and well-being, focused on advancing the ability to assess the health of the ongoing pregnancy by developing biomarkers and “omics” of the placenta, and advanced imaging and other measurements to assess troubled pregnancies. The next difficult step will be to intervene in troubled pregnancies by translating knowledge gained into placental therapeutics to improve fetal health. To provide a novel and safe way of administering therapies to the placenta, we have developed targeted liposomes decorated with specific placental homing peptides. Heretofore, these approaches have been limited to mouse models for in vivo targeting, and progress in addressing experimental fetal growth restriction has been made. However, there are limitations to the rodent model, and nonhuman primates (NHP) have enhanced relevance to human placentation, and are a more clinically relevant model for experimental therapeutic approaches. We hypothesize that peptide-decorated liposomes that selectively accumulate in the mouse placenta will also target the primate placenta in vivo. We propose to use the rhesus macaque in this R21 Exploratory/Developmental proposal with two Specific Aims: Aim 1. To determine if trophoblast-targeted liposomes decorated with the iRGD peptide sequence are taken up by the placenta in vivo in an NHP model. We will adapt reagents and methods effective in human placental explants in vitro, and the mouse in vivo, to NHP models and assess safety both in the dam and the fetus, including maternal and fetal tissue histopathology, inflammatory and immune responses at the MFI, and maternal physiological responses to placental therapy. Aim 2. To determine if liposomes decorated with peptides shown to target the murine uterine vasculature are taken up in NHP uterine vessels including spiral arteries. We will assess the distribution of CNKGLRNK-decorated liposomes at the MFI and monitor uterine blood flow following treatment with liposomes. This proposal brings together strengths from both research teams. The Harris lab has published experience with liposome nanoparticles targeting human explants in vitro, and the mouse placenta in vivo. The Golos lab has published experience in NHP pregnancy, imaging the fetus and placenta, and histopathology of the maternal-fetal interface. We will determine if the liposomes can target the NHP placenta and uterine vessels, and if the cargo is transferred to the fetus. These studies will allow NHP investigators to work towards the ultimate goal, to be able to “treat the placenta” to improve the health of both mothers and babies.

NICHD启动了人类胎盘项目（HPP），以改善孕产妇和胎儿/新生儿的健康和福祉，重点是通过开发胎盘的生物标志物和“组学”以及先进的成像和其他测量来评估妊娠问题，从而提高评估正在进行的妊娠健康的能力。下一个困难的步骤将是通过将所获得的知识转化为胎盘疗法来干预有问题的妊娠，以改善胎儿健康。为了提供一种新的和安全的方式给药治疗胎盘，我们已经开发了靶向脂质体修饰特定的胎盘归巢肽。因此，这些方法仅限于用于体内靶向的小鼠模型，并且在解决实验性胎儿生长限制方面取得了进展。然而，啮齿动物模型存在局限性，非人灵长类动物（NHP）与人类胎盘形成的相关性增强，是实验治疗方法的临床相关性更高的模型。我们假设肽修饰的脂质体选择性地在小鼠胎盘中积累，也将靶向体内灵长类动物胎盘。我们建议在本R21探索/开发提案中使用恒河猴，有两个特定目的：目的1。确定在NHP模型中，用iRGD肽序列修饰的滋养层靶向脂质体是否被体内胎盘摄取。我们将调整试剂和方法，在体外人胎盘外植体有效，在体内的小鼠，NHP模型和评估安全性在母体和胎儿，包括母体和胎儿组织病理学，炎症和免疫反应在MFI，和母体的生理反应胎盘治疗。目标二。确定修饰有靶向鼠子宫血管的肽的脂质体是否被NHP子宫血管（包括螺旋动脉）吸收。我们将评估CNKGLRNK修饰的脂质体在MFI处的分布，并监测脂质体治疗后的子宫血流。这一建议汇集了两个研究团队的优势。哈里斯实验室已经发表了脂质体纳米颗粒体外靶向人类外植体和体内小鼠胎盘的经验。Golos实验室已经发表了NHP妊娠、胎儿和胎盘成像以及母胎界面组织病理学方面的经验。我们将确定脂质体是否可以靶向NHP胎盘和子宫血管，以及货物是否转移到胎儿。这些研究将使NHP研究人员能够朝着最终目标努力，能够“治疗胎盘”，以改善母亲和婴儿的健康。